coteauBeta Get App

NAUT

Nautilus Biotechnology, Inc.
$3.24
+24.62% Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-33%+36%+104%+173%+242%Oct 2025Oct 2026Apr 202652w high $4.3152w low $0.84
NAUTSPY
1W
+57.3%
1M
+239.6%
3M
+91.7%
6M
+23.7%
YTD
+66.2%
1Y
+123.4%

Live chart

Loading live chart…

What they do

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for NAUT yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
GlobeNewswire · Oct 15
Nautilus Biotechnology Files $300 Million Shelf Registration
MT Newswires · Sep 11
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
GlobeNewswire · Sep 04
Nautilus Biotechnology Inc (NAUT) Q2 2026 Earnings Call Highlights: Strategic Shifts and ...
GuruFocus.com · Jul 28
Nautilus Biotechnology Q2 Earnings Call Highlights
MarketBeat · Jul 28

Key stats

Market value$351.9M
P/E (next 12 months, estimated)-3.7
52-week range$0.84 – $4.31
Dividend yieldNo dividend
Analyst consensusStrong Buy (3)
Average analyst price target$3.83 (+18%)
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

Earnings

NAUT earningsNext report in 4 days
Next report · quarter Sep 2026
Tue Oct 27, 2026Before the open
EPS consensus-$0.16
Revenue consensus$206.2K 4 analysts
Last 4 quarters · EPS vs estimate
Jul 28, 2026-$0.11est -$0.14+21.4%Above estimates
Apr 28, 2026-$0.12est -$0.14+17.2%Above estimates
Feb 26, 2026-$0.11est -$0.14+21.4%Above estimates
Oct 28, 2025-$0.11est -$0.15+26.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 12:05:00 ET
24-1025-0225-0425-0725-1026-0226-0426-07-0.170.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$10.0K–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–
Rating changes
Initiated
2026-09-29 · Roth Capital started covering NAUT at Buy
Initiated
2026-09-09 · Leerink Partners started covering NAUT at Outperform
Reiterated
2026-02-27 · Guggenheim reiterated Buy on NAUT
Downgrade
2024-12-05 · Goldman Sachs downgraded NAUT from Neutral to Sell
Initiated
2024-06-27 · Guggenheim started covering NAUT at Buy
Reiterated
2023-08-03 · Morgan Stanley reiterated Equal-Weight on NAUT

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-21 12:05:00 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026